Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SRPT stock price vs MRNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRNA's multiple
Needs MRNA P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SAREPTA THERAPEUTICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
PFIZER INC
SRPT vs PFE
JOHNSON & JOHNSON
SRPT vs JNJ
GILEAD SCIENCES, INC.
SRPT vs GILD
NOVAVAX INC
SRPT vs NVAX
VERTEX PHARMACEUTICALS INC / MA
SRPT vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SRPT can sustain 15.6% revenue growth and avoid further margin deterioration, then the stock may be attractive as a deep value relative play because it trades at 0.8x P/S versus MRNA's 9.3x; however, if profitability and quality remain weak, the current price near the low end of its historical band may already reflect most of the upside case.
On a P/S basis, SRPT trades at 0.8x versus MRNA at 9.3x, which mechanically produces a very large implied upside in the provided framework. However, SRPT is already near the low end of its historical valuation band, so much of the apparent discount may already be reflected in the current price.
Supporting Metrics
